Lenacapavir hailed as HIV prevention breakthrough amid access concerns
A twice-a-year injection of lenacapavir showed high efficacy in clinical trials, raising questions about global access and funding disparities.
A twice-a-year injection of lenacapavir showed high efficacy in clinical trials, raising questions about global access and funding disparities.